Company news
Marijuana Inc. news in 2026
Marijuana Inc.'s news releases, calls and decks from 2026, newest first.
NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
October 7, 2026
NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technology
September 29, 2026
NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference
September 25, 2026
NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion
August 6, 2026
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
August 5, 2026
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
July 28, 2026
NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform
July 22, 2026
NexTel Medical Corp. Announces Strategic Exit from Cannabis and CBD Sector to Pivot 100% to Wellness and Healthcare
July 8, 2026
NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth
June 17, 2026
NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University
June 9, 2026
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
June 2, 2026
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist
May 11, 2026
NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test
April 7, 2026
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
March 16, 2026
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
March 5, 2026
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
February 10, 2026